<DOC>
	<DOCNO>NCT01078298</DOCNO>
	<brief_summary>Patients depression tend high prevalence smoke well increase severity nicotine dependence . Phase 2 Phase 3 varenicline clinical trial demonstrate efficacy tolerability include subject depression . This smoking cessation study focus depressed population ass efficacy safety varenicline .</brief_summary>
	<brief_title>Safety And Efficacy Of 12 Weeks Of Varenicline For Smoking Cessation In Smokers With Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Varenicline</mesh_term>
	<criteria>Male female cigarette smoker , 1875 year , motivate stop smoking consider suitable smoking cessation attempt Smoked average least 10 cigarette per day past year past month , exhale carbon monoxide ( CO ) &gt; 10 ppm screen Current past diagnosis MDD without psychotic feature , either single recurrent , use DSM IV TR base clinical assessment confirm SCID least one follow : On stable antidepressant treatment MDD ( stable dose least 2 month ) Major depressive episode , use DSM IV TR , past 2 year successfully treat Current past diagnosis dementia , schizophrenia , schizoaffective disorder , psychotic disorder , bipolar I disorder , bipolar II disorder . Subjects antisocial , schizotypal , personality disorder severe enough compromise subject 's ability comply study requirements.. Current use either bupropion nortryptiline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>smoking</keyword>
	<keyword>smoke cessation</keyword>
	<keyword>smoke cessation depress subject</keyword>
</DOC>